News

Older people in low-income countries are especially at risk for COVID-19.

The European Union is rethinking its approach to border crossings as the region deals with the COVID-19 pandemic.

FDA grants emergency use authorization for Cepheid's point-of-care COVID-19 diagnostic, Xpert Xpress SARS-CoV-2.

Lopinavir-ritonavir worked against SARS, but it had little effect against coronavirus compared to standard care.

Here is a look at infectious disease-related FDA news from the week of March 15, 2020.

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Stay on top of coronavirus developments from March 20, 2020.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New analyses of the novel coronavirus and previously circulating SARS viruses reveal promising immunologic targets for vaccine against COVID-19.

Events that host at-risk people should consider canceling, postponing, or limiting in-person attendance.

The FDA has issued Emergency Use Authorization for another COVID-19 test, produced by Genmark Diagnostics.

A new paper describes how one Singaporean hospital responded to the 2003 severe acute respiratory syndrome (SARS) outbreak, and how those lessons can inform the response to the current pandemic.

The agency notes that they are working closely with industry officials to expedite efforts to develop countermeasures for COVID-19.

Stay on top of coronavirus developments from March 19, 2020.

George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.

The FDA approved a combination therapy of sofosbuvir and velpatasvir to treat children with hepatitis C virus.

The US government has ambitious goals to expand the number of people tested and treated for HIV in the coming years. A new study details the best interventions to make the biggest difference for the most people.

The FLU-v experimental vaccine designed to protect across influenza strains showed promising results in a recent clinical trial.

The 20vPnC pneumococcal conjugate vaccine candidate was found comparable to licensed products in safety and immunogenicity.

A new influenza vaccine, the global burden of the flu in children, and the CDC’s latest numbers on the flu disease dominates the flu update this month.

A drug known to inhibit a cellular protease TMPRSS2 could potentially be a novel therapeutic intervention for COVID-19 infections, according to German investigators who found that the cellular protein may allow entry of SARS-CoV-2 into lung cells.

The NIH has shared new information on the stability of SARS-CoV-2 virus on a variety of surfaces.

According to Abbott, the systems can run high volumes of up to 470 tests in 24 hours.

Stay on top of coronavirus developments from March 18, 2020.

An American physics teacher living in Nanjing, China shares his experience with the coronavirus outbreak response.

The FDA has issued new guidance for conducting clinical trials during the COVID-19 pandemic.

In a new study, 38% of inpatients with bacteremia at an academic medical center had low procalcitonin values.

In the midst of the ongoing COVID-19 pandemic, it’s easy to forget that the United States was already in the midst of a crisis before the virus arrived on these shores: the opioid epidemic.